

Closing Remarks

Peter J. Späth
Institute of Pharmacology
University of Berne, Berne
Switzerland
peter.spaeth@pki.unibe.ch



General comments

Awards
Experts' lectures
Basic science
Genetics
Trials

Trials
Treatment
options
Diagnosis
HAE-nC1-INH
Scoring & QoL
Registries,
Cohorts,
Centers,
Organisations
Farewell

Non-Conventional Diagnostics

GENES AND CASCADES

THE ATTACK IN THE LIMELIGHT

SORTING THINGS OUT: HAE-FXII

MANAGEMENT FINE-TUNED

ANGIOEDEMA AVALANCHE

THE SHADES OF FREEDOM — NURSING ROUND TABLE DISCUSSION → foundation of the «HAE International Nursing Organization»

LIVING WITH HAE AROUND THE WORLD

MIXING IT WITH THE AUTHORS – SCIENCE IN THE SHOP-WINDOW

SOCIAL PROGRAMS



General comments

Awards
Experts' lectures
Basic science
Genetics
Trials

Treatment
options
Diagnosis
HAE-nC1-INH
Scoring & QoL
Registries,
Cohorts,
Centers,
Organisations

Farewell

This was a great and very fruitful meeting!

The plaudit goes also to Diamond company
The satisfaction of Konrad Bork – Session HAE-FXII
Proposal: next WS giving satisfaction to the Milan

My satisfaction

Achieved to put complement into the right context

group by having a Surprise Session! (O-24)

- Not the immune complex-mediated but a pattern recognizing pathway-mediated activation of interest
- The interconnection to inflammation interconnection of lectin pathway and contact activation on various levels
- Disease modifying
- Diagnostic tests shifting to contact activation proteins
 My dissatisfaction
- The name of the WS not reflecting the move



General comments

Awards

Experts' lectures
Basic science
Genetics

Trials
Treatment
options
Diagnosis
HAE-nC1-INH
Scoring & QoL
Registries,
Cohorts,
Centers,
Organisations
Farewell

"For HAE Patients": warm congratulations to Henriette and Lilian for continuous enthusiasm through decades

"For HAE Research": congratulations to Dr. Kaplan,

USA



Even as awardee there is no free lunch!



"Grant for Young Investigators": the four grants go to

- Csuka Dorottya, Hungary (oral 2nd time)
 Activation of the ficolin-lectin pathway during attacks of hereditary angioedema
- Madsen Daniel, Denmark (oral)
 Immunological method for specific measurement of C1-inh polymers in plasma and C1-inh concentrate
- López Lera Alberto, Spain (poster, 2nd time)
 No evidence for disease-modifier genes in the PBMC expression profile from HAE patients in basal conditions. An RNA-based microarray screening
- Szabó Erika & Zotter Zsuzsanna, Hungary (poster)
 Home treatment of attacks with conestat alfa in hereditary
 angioedema due to C1-inhibitor deficiency (HAE-C1-INH)
- Thanks to the industry for the generous sponsoring



- Francois Marceau, Canada: Bradykinin receptors: agonists, antagonists, expression, signaling and adaptation to sustained stimulation
- Coen Maas, The Netherlands: The protease storm of angioedema
- Peter Gál, Hungary: Activation and regulation of the lectin pathway of the complement system
- Allen Kaplan, USA: "For HAE Research" prize-winner lecture
- BK: cardinal signs of inflammation dependent on vascular responses, e.g. receptors (Marceau, Maas)
- Why blood coagulation activation remains marginal? (Maas, Kaplan, others)
 - Discrepancy in vivo facts and in vitro diagnostic testing
 - Complexity of FXII activation: FXIIa (αFXIIa & surface) vs FXIIf (βFXIIa, not surface bound)
- For understanding & optimal treatment in the future we will need learning, learning, learning!



Awards
Experts' lectures
Basic science
Genetics

Trials

Treatment
options
Diagnosis
HAE-nC1-INH
Scoring & QoL
Registries,
Cohorts,
Centers,
Organisations
Farewell

FXII gene: new deletion in Turkish families

SERPING1

- De-novo homozygous mutation of C1-INH gene
- Regulation total vs allele-specific mRNA at the transcriptional level
- Number of mutations increasing and increasing (Brazil)
- Gneotype → phenotype: remains controversial, very large numbers of patient data might help

Microarray techniques

- PLAUR (uPAR) & ADM
- PBMC no clear-cut results; HSP90? (from Dr.Kaplan's presentation)



Awards
Experts' lectures
Basic science
Genetics

Trials

Treatment
options
Diagnosis
HAE-nC1-INH
Scoring & QoL
Registries,
Cohorts,
Centers,
Organisations
Farewell


- The wave of big clinical HAE trials ebbs away
- Some industry catching up
- Completing marketing authorizations: pediatric, subcutaneous, self-administration
- QoL studies
- Outlook: monoclonal(s) → half-life↑



- A possible duty of the audience: minimum requirement treatment to be established?
- Overviews of treatments: not to forget outlining of evolution of data collection
- Adverse events
 - Agreement how to assess
 - Not to forget mentioning (accumulative) doses
- Presentation of results: impressioning statistics nevertheless, how about (estimation of) biological relevance?
- Long-term prophylaxis vs on demand: number of attacks can be reduced but not prevented; a question of healthcare politics – does this audience take the lead?



- Women with HAE
 - Progestins
 - Breast cancer: GnHR analogs
- Early in attack development!
- Self-administration children
- Future: guided, personalized
- Observational data from daily use: comparison of efficacy of drugs emerge
- Pharmacoeconomic assessments might become possible





Farewell

- Various diagnostic tests of contact activation and control are popping up
- Feasibility of routine application to be shown
- Everything around bradykinin assessment >
 proposal: invite next time for discussion an expert
 on BK assessment
- Consensus how to collect blood/plasma for these new tests (cocktail of inhibitors needed?)
- Value of target enzyme-inhibitor complexes when using the right cocktail of inhibitors)?



General
comments
Awards
Experts' lectures
Basic science
Genetics
Trials
Treatment
options
Diagnosis

HAE-nC1-INH

Scoring &

QoL

Registries,
Cohorts,
Centers,
Organisa-tions
Farewell

- Congratulation the baby is born!
 - Health Related Quality of Life (HRQoL) as measured by SF-36v2 in adults with Hereditary Angioedema due to C1-inhibitor deficiency
- Other questionnaires presented which one the best/to select for which type of questions in future?
- Additional efforts ongoing (pharmacoeconomics)



Farewell

- Registries/Population studies
 - Greece
 - Latin America
 - Macedonia
 - Romania
 - Slovenia
 - South Africa
 - Sweden
 - Switzerland
- HAE patient organization in individual countries & HAEi



Our fugacy – but life is going on; as the French say: le roi est mort, vive le roi!

For us: The spiritus rector of the C1-INH Deficiency Workshops is dead – let's hurrah the Angels!

With the very successful organization of this Workshop the Angels have demonstrated that they can fly by their own wings.



Have a safe trip home See you latest in two years